Jerusalem/Needham (PRWEB) March 21, 2011
Oridion (SIX Swiss Exchange: ORIDN), creator of the Smart Capnography™ family of decision support tools for monitoring effective ventilation, today announced the presentation of five abstracts addressing the use of capnography monitoring in multiple clinical applications at four professional society conferences in May and June. These follow the presentation of eight capnography-related abstracts at the Society of Technology in Anesthesia (STA) Annual Conference, January 12-15 in Las Vegas, Nevada.
Going far beyond standard measures of respiratory rate, capnography provides continuous monitoring of a patient's adequacy of ventilation by measuring end-tidal carbon dioxide (etCO2) through breath waveforms.
Continued Clinical Research Focused on the Value of Capnography
Leading clinicians and researchers, including three investigators from Oridion, have been invited to present clinical findings addressing capnography as a measure of adequacy of ventilation in multiple applications, including labor analgesia and the screening of obstructive sleep apnea patients.
- Among the upcoming abstracts to be presented is "A Pilot Evaluation of a Novel Screening Tool for Sleep Related Breathing Disorders." It will be presented at the annual meeting of the American Academy of Sleep Medicine (AASM), June 11-15 in Minneapolis, Minnesota. This study of 39 patients concludes that capnography is an effective tool for screening and assisting in the diagnosis of adult patients with medium and severe Obstructive Sleep Apnea.
- The first of two abstracts to be presented at the European Society of Anesthesiology's Euroanesthesia 2011 Conference, June 11-14 in Amsterdam is "A Prospective Randomized Controlled Trial to Compare the Efficacy and Safety of Remifentanil IV PCA to Epidural PCEA in Labor Analgesia." Researchers in this study determined the need for continuous respiratory monitoring in order to detect maternal desaturation during the use of Remifentanil. The second abstract is "Integrated Pulmonary Index™ Reflects Respiratory Function after Elective Coronary Artery Bypass Grafting." The Integrated Pulmonary Index (IPI) is part of the Smart Capnography™ family of decision support tools, which integrate four key parameters (end-tidal CO2, respiratory rate, pulse rate, and SpO2) into a single index value. Researchers in this study concluded that during the early postoperative period after CABG, IPI can predict the success of tracheal extubation and reflect changes in respiratory function.
- Another abstract addressing the use of IPI, "The Value of Integrated Pulmonary Index (IPI) Monitoring During Endoscopies in Children," will be presented at the annual Digestive Disease Week conference, May 7-10, in Chicago, Illinois. In a study of 109 pediatric endoscopic patients who were administered propofol sedation, with or without midazolam and fentanyl, IPI detected all 58 occurrences of apnea and 26 occurrences of hypoxia, while pulse oximetry detected only the hypoxia episodes. Researchers concluded: "IPI monitoring adds to patient safety during endoscopic procedures."
- "Capnography: Collaborating for Better Patient Care" will be presented during the annual meeting of the Society of Gastroenterology Nurses and Associates (SGNA), May 6-11 in Indianapolis, Indiana. This abstract, authored by Katrina Swartz RN of the Winchester Medical Center in Virginia, addresses an IRB-approved collaboration between a clinical nursing group and the design team at Oridion to test investigational designs for improvement of the Smart CapnoLine Guardian™, an airway management system for breath sampling during upper endoscopic procedures. The collaboration resulted in improvements to the CapnoLine Guardian to successfully enable continuous CO2 monitoring and oxygen delivery during upper endoscopy procedures.
For further Oridion information please contact:
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
phone: +972 2 589 9159
address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States and Israel.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective and proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.
Certain statements made herein that are not historical are forward-looking. The words "estimate," "project," "intend," "expect," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology. The Company does not assure any obligation to update the forward looking information contained in this press release.
# # #